<a href='https://providers.clevelandclinic.org/provider/luke-laffin/4268377'>Luke Laffin, MD</a>, speaks with <a href='https://providers.clevelandclinic.org/provider/steven-nissen/4268279'>Steven Nissen, MD</a>, about findings from the ALPACA trial evaluating lepodisiran and its effects on oxidized phospholipids and lipoprotein(a). They discuss the potential mechanisms linking lipoprotein(a) to cardiovascular risk and how ongoing phase 3 research may shape future management of patients with elevated lipoprotein(a). Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469. <a href='https://consultqd.clevelandclinic.org/oxidized-phospholipids-track-closely-with-lpa-reductions'>Learn more</a>.

Luke Laffin, MD, speaks with Steven Nissen, MD, about findings from the ALPACA trial evaluating lepodisiran and its effects on oxidized phospholipids and lipoprotein(a). They discuss the potential mechanisms linking lipoprotein(a) to cardiovascular risk and how ongoing phase 3 research may shape future management of patients with elevated lipoprotein(a).  Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.  Learn more. 

Lepodisiran and the Emerging Role of Oxidized Phospholipids in Lipoprotein(a) Risk

Description